Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion

Biochemical and Biophysical Research Communications

Volumn 394, Issue 4, 2010, Pages 1042-1046

  Asaoka, Yoshinari ^a   Tada, Motohisa ^b   Ikenoue, Tsuneo ^a   Seto, Motoko ^a   Imai, Mitsuho ^a   Miyabayashi, Koji ^a   Yamamoto, Keisuke ^a   Yamamoto, Shinzo ^a   Kudo, Yotaro ^a   Mohri, Dai ^a   Isomura, Yoshihiro ^a   Ijichi, Hideaki ^a   Tateishi, Keisuke ^a   Kanai, Fumihiko ^b   Ogawa, Seishi ^a   Omata, Masao ^a   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

c Met; Gastric cancer; Gene amplification; Receptor tyrosine kinase; Splice site mutation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; SCATTER FACTOR RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CELL STRAIN HS746T; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DNA DETERMINATION; DNA SEQUENCE; DOWN REGULATION; GENE AMPLIFICATION; GENE DELETION; GENE LOCUS; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; JUXTAMEMBRANE DOMAIN DELETION; LUNG CANCER; MUTATION; PRIORITY JOURNAL; STOMACH CANCER; UBIQUITINATION; WESTERN BLOTTING;

BASE SEQUENCE; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 7; DNA MUTATIONAL ANALYSIS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MUTATION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MET; RNA SPLICE SITES; RNA SPLICING; SEQUENCE DELETION; STOMACH NEOPLASMS;

EID: 77950859967     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.03.120     Document Type: Article

References (24)

1. Marshall C.J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80 (1995) 179-185
2. Lin W., Kao H.W., Robinson D., Kung H.J., Wu C.W., and Chen H.C. Tyrosine kinases and gastric cancer. Oncogene 19 (2000) 5680-5689
3. Ming S.C. Cellular and molecular pathology of gastric carcinoma and precursor lesions: a critical review. Gastric Cancer 1 (1998) 31-50
4. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., and Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
5. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., and Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
6. Tsuchihashi Z., Khambata-Ford S., Hanna N., and Janne P.A. Responsiveness to cetuximab without mutations in EGFR. N. Engl. J. Med. 353 (2005) 208-209
7. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C.H., Steger G., Huang C.S., Andersson M., Inbar M., Lichinitser M., Lang I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T.M., Ruschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M.S., and Gelber R.D. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1659-1672
8. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel V.G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., and Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1673-1684
9. Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J. Natl. Cancer Inst. 101 (2009) 1306-1307
10. Comoglio P.M., Giordano S., and Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 7 (2008) 504-516
11. Turner N., and Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 10 (2010) 116-129
12. M. Tada, F. Kanai, Y. Tanaka, M. Sanada, Y. Nannya, K. Tateishi, M. Ohta, Y. Asaoka, M. Seto, F. Imazeki, H. Yoshida, S. Ogawa, O. Yokosuka, M. Omata, Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism array in gastric cancer, Cancer Sci. (2010), in press [Epub ahead of print].
13. Nannya Y., Sanada M., Nakazaki K., Hosoya N., Wang L., Hangaishi A., Kurokawa M., Chiba S., Bailey D.K., Kennedy G.C., and Ogawa S. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res. 65 (2005) 6071-6079
14. Yamamoto G., Nannya Y., Kato M., Sanada M., Levine R.L., Kawamata N., Hangaishi A., Kurokawa M., Chiba S., Gilliland D.G., Koeffler H.P., and Ogawa S. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am. J. Hum. Genet. 81 (2007) 114-126
15. Guleng B., Tateishi K., Ohta M., Asaoka Y., Jazag A., Lin L.J., Tanaka Y., Tada M., Seto M., Kanai F., Kawabe T., and Omata M. Smoothened gene mutations found in digestive cancer have no aberrant Hedgehog signaling activity. J. Gastroenterol. 41 (2006) 1238-1239
16. Jang J.H., Shin K.H., and Park J.G. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 61 (2001) 3541-3543
17. Lee J.W., Soung Y.H., Seo S.H., Kim S.Y., Park C.H., Wang Y.P., Park K., Nam S.W., Park W.S., Kim S.H., Lee J.Y., Yoo N.J., and Lee S.H. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin. Cancer Res. 12 (2006) 57-61
18. Chen Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M., Wang L., Soda M., Kikuchi A., Igarashi T., Nakagawara A., Hayashi Y., Mano H., and Ogawa S. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455 (2008) 971-974
19. Leary R.J., Lin J.C., Cummins J., Boca S., Wood L.D., Parsons D.W., Jones S., Sjoblom T., Park B.H., Parsons R., Willis J., Dawson D., Willson J.K., Nikolskaya T., Nikolsky Y., Kopelovich L., Papadopoulos N., Pennacchio L.A., Wang T.L., Markowitz S.D., Parmigiani G., Kinzler K.W., Vogelstein B., and Velculescu V.E. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc. Natl. Acad. Sci. USA 105 (2008) 16224-16229
20. Lee J.H., Han S.U., Cho H., Jennings B., Gerrard B., Dean M., Schmidt L., Zbar B., and Vande Woude G.F. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19 (2000) 4947-4953
21. Kim I.J., Park J.H., Kang H.C., Shin Y., Lim S.B., Ku J.L., Yang H.K., Lee K.U., and Park J.G. A novel germline mutation in the MET extracellular domain in a Korean patient with the diffuse type of familial gastric cancer. J. Med. Genet. 40 (2003) e97
22. Kong-Beltran M., Seshagiri S., Zha J., Zhu W., Bhawe K., Mendoza N., Holcomb T., Pujara K., Stinson J., Fu L., Severin C., Rangell L., Schwall R., Amler L., Wickramasinghe D., and Yauch R. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 66 (2006) 283-289
23. Dibb N.J., Dilworth S.M., and Mol C.D. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat. Rev. Cancer 4 (2004) 718-727
24. Bachleitner-Hofmann T., Sun M.Y., Chen C.T., Tang L., Song L., Zeng Z., Shah M., Christensen J.G., Rosen N., Solit D.B., and Weiser M.R. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol. Cancer Ther. 7 (2008) 3499-3508